Agilent Technologies Inc (A)

Sep 23, 2026

This article examines the investment performance of Agilent Technologies (A) over the past decade. A $1000 investment in Agilent Technologies ten years ago would now be worth $3,583.89, representing a 258.39% gain, outperforming both the S&P 500 and gold over the same period. Analysts are optimistic about Agilent's future, citing sustained instrument demand, pharma exposure, and recent product launches.

Sep 23, 2026

Agilent Technologies (NYSE: A) experienced a 3.29% surge, closing at $167.26, indicating a strong bullish trend. However, technical indicators like RSI show the stock is significantly overbought on daily and hourly charts, suggesting a potential near-term pause or pullback. Key levels to watch include the daily pivot at $165.29 and resistance at $169.55 to determine if the rally will continue or if a correction is imminent.

Sep 22, 2026

Shares of Agilent Technologies Inc. rose by 3.29% to $167.26 on Tuesday, marking its sixth consecutive day of gains. This strong performance occurred during a mixed trading session for the broader stock market, where the S&P 500 Index remained mostly unchanged and the Dow Jones Industrial Average saw a slight decline.

Sep 22, 2026

Agilent Technologies, Inc. (A) has broken above its previous price target of $158.00 with increased trading volume, maintaining a bullish outlook. The stock is supported by its 50-day Simple Moving Average and an ascending trendline, with momentum indicators also signaling continued upward movement. The next target resistance level is projected at $169.50, provided the stock stays above $158.00.

Sep 19, 2026

Agilent Technologies (A) has launched a new slide scanner, the Agilent S540MD, in the U.S., capable of holding 540 glass slides. This FDA-cleared device aims to help pathology labs digitize their workflows and prepare for AI assistance, leveraging Agilent's expertise despite the underlying hardware being from Hamamatsu. The launch follows a strong financial quarter for Agilent, though the full impact of the scanner on revenue remains to be seen.

Sep 15, 2026

The article reviews the Q2 performance of Revvity (NYSE:RVTY) and other companies in the research tools & consumables industry. It highlights Revvity's strong quarter with revenues of $711.1 million, while also detailing the best performer, Avantor (NYSE:AVTR), and the weakest, Bruker (NASDAQ:BRKR), among its peers. The sector as a whole reported strong Q2 results, with revenues beating consensus estimates by 1.7%.